⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1316573 | 0.46 | NOS1 (0.40) | — | |
| SCHEMBL56632 | 0.38 | — | — | |
| SCHEMBL121778 | 0.35 | — | — | |
| SCHEMBL108935 | 0.35 | — | — | |
| Piperazine SCHEMBL31711465 | 0.32 | — | — | |
| SCHEMBL380648 | 0.30 | — | — | |
| SCHEMBL28069489 | 0.30 | — | — | |
| SCHEMBL29865 | 0.29 | — | — | |
| SCHEMBL1198563 | 0.29 | — | — | |
| Aziridine SCHEMBL2267 | 0.29 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10435388-B2 | Selective inhibitors of clinically important mutants of the EGFR tyrosine kinase | CS PHARMATECH LIMITED (KY) | 2019-10-08 | — | — | US | disclosed |
| US-20190023689-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | HIGH GREAT INVESTMENT LIMITED (HK) | 2019-01-24 | — | — | US | disclosed |
| US-5608056-A | Substituted 3-pyrrolidinylthio-carbapenems as antimicrobial agents | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-03-04 | — | — | US | disclosed |
| EP-0636133-A1 | SUBSTITUTED 3-PYRROLIDINYLTHIO-CARBAPENEMS AS ANTIMICROBIAL AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-02-01 | — | — | EP | disclosed |
| WO-1993021186-A1 | SUBSTITUTED 3-PYRROLIDINYLTHIO-CARBAPENEMS AS ANTIMICROBIAL AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-10-28 | — | — | WO | disclosed |